PULSE BIOSCIENCES INC (PLSE)

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants

Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery

Get An Even Better Deal On PLSE Than Director Duggan Did

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024

PLSE Stock Earnings: Pulse Biosciences Reported Results for Q2 2024

Pulse Biosciences just reported results for the second quarter of 2024.

PLSE Stock Earnings: Pulse Biosciences Reported Results for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pulse Biosciences (NASDAQ:PLSE) just reported results for the second quarter of...

Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Commit To Buy Pulse Biosciences At $11, Earn 31.7% Annualized Using Options

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Pulse Biosciences, Inc. (NASDAQ: PLSE)

/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Pulse Biosciences, Inc. (NASDAQ: PLSE) on behalf of the company's shareholders. The...

Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc. Announces the Closing of its Rights Offering

Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering

Top Buys by Directors: Duggan's $9.4M Bet on PLSE

Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000

Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting

Pulse Biosciences Enhances Executive Leadership Team

Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

PLSE Stock Earnings: Pulse Biosciences Reported Results for Q1 2024

Pulse Biosciences just reported results for the first quarter of 2024.

PLSE Stock Earnings: Pulse Biosciences Reported Results for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pulse Biosciences (NASDAQ:PLSE) just reported results for the first quarter of ...

Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results

Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000

Bullish Two Hundred Day Moving Average Cross - PLSE